Latin America Legal Chronicle. February 11, 2022

Takeda’s Agreement with Adium Pharma

By Ambrogio Visconti

Marval O’Farrell Mairal advised Takeda on the transaction Takeda Pharmaceutical Company Limited  (TSE:4502/NYSE:TAK) has entered into an agreement to divest a selection of non-core products from the...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here